Innovator’s Pitch Challenge

Interested in Connecting? Please contact:

Mikkel Dybkjaer

Message the company or request a 1:1 meeting here

Company Description

Hoba Therapeutics is developing innovative treatments for multiple indications within chronic pain disorders and hearing loss; indications with a large, worldwide unmet medical need for safe and efficacious treatments. Our compounds are therapeutic proteins and the only members of a family of recently discovered neurotrophic factors. Our data show that these molecules have unique actions on sensory nerve cell and their surrounding support cells. Our compounds have a unique mode of action providing long-lasting, disease-modifying effects with an attractive safety profile (non-addictive). – HB-086: Potentially the first long-acting, disease-modifying, non-opioid treatment for neuropathic pain differentiating to SoC and competing programs – HB-097: Potential to be the first preventive and disease-modifying treatment for hearing loss We are entering the large indications through gateway indications with strong scientific, clinical and commercial rationales; Chemotherapy-Induced Peripheral Neuropathy with significant unmet medical need and USD +2B market value, and Ototoxic Hearing Loss. We are collaborating with universities in the US and EU (e.g. Yale, Texas, Arizona, Madrid, Hannover, Copenhagen) and NIH’s Helping to End Addiction Long-term Initiative. Hoba Therapeutics is based in Denmark, and led by an experienced management team with in-depth pain R&D experience – and proven track record of multiple exits Seeking EUR 40 M in a Series A supported by current investors

Pitch Deck

Executive Summary

Pitch Video